{{Onesource|date=November 2007}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464380213
| IUPAC_name = (2β,3α,5α,16β,17β)-3-(acetyloxy)-16-(1-allylpiperidinium-1-yl)-2-piperidin-1-yl-17-(propionyloxy)androstane bromide
| image = Rapacuronium bromide.svg
| width = 250
| caption = Rapacuronium bromide
<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = C
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US_comment = Withdrawn
| routes_of_administration = [[Intravenous therapy|Intravenous]]
<!--Pharmacokinetic data-->
| bioavailability = Not applicable
| protein_bound = Variable
| metabolism = [[Hydrolysis|Hydrolyzed]] to active metabolites<br />[[Cytochrome P450 oxidase|CYP]] system not involved
| elimination_half-life = 141 minutes (mean)
| excretion = [[Kidney|Renal]] and fecal
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 156137-99-4
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 5311398
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB04834
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4470889
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201352
<!--Chemical data-->
| C=37 | H=61 | N=2 | O=4| charge = + 
| molecular_weight = 597.891 g/mol
| smiles = [Br-].O=C(O[C@H]6[C@@H]([N+]1(C\C=C)CCCCC1)C[C@@H]5[C@]6(C)CC[C@H]3[C@H]5CC[C@H]4C[C@H](OC(=O)C)[C@@H](N2CCCCC2)C[C@]34C)CC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C37H61N2O4.BrH/c1-6-20-39(21-12-9-13-22-39)32-24-30-28-15-14-27-23-33(42-26(3)40)31(38-18-10-8-11-19-38)25-37(27,5)29(28)16-17-36(30,4)35(32)43-34(41)7-2;/h6,27-33,35H,1,7-25H2,2-5H3;1H/q+1;/p-1/t27-,28+,29-,30-,31-,32-,33-,35-,36-,37-;/m0./s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = LVQTUXZKLGXYIU-GWSNJHLMSA-M
| synonyms = <small>[(2''S'', 3''S'', 5''S'', 8''R'', 9''S'', 10''S'', 13''S'', 14''S'', 16''S'', 17''S'')-3-acetyloxy-10,13-dimethyl-2-(1-piperidyl)-16-(1-prop-2-enyl-3,4,5,6-tetrahydro-2''H''-pyridin-1-yl)-2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,11 ,12 ,14, 15, 16, 17-tetradecahydro-1''H''-cyclopenta[''a'']phenanthren-17-yl]propanoate</small>
}}

'''Rapacuronium bromide''' (brand name '''Raplon''') is a rapidly acting, non-depolarizing [[aminosteroid]] [[neuromuscular-blocking drugs|neuromuscular blocker]] formerly used in modern [[anaesthesia]], to aid and enable [[endotracheal intubation]], which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in [[intensive care]]. As a non-depolarizing agent it did not cause initial stimulation of muscles before weakening them.

Due to risk of fatal [[bronchospasm]] it was withdrawn from the [[United States]] market by [[Organon International|Organon]] on March 27, 2001, less than 2 years after its FDA approval in 1999.<ref>Shapse, Deborah (March 27, 2001). {{cite web|url= http://www.fda.gov/medwatch/SAFETY/2001/raplon_DDR.pdf |title=Voluntary Market Withdrawal }}&nbsp;{{small|(10.8&nbsp;[[Kibibyte|KiB]])}}. [[Organon International]]. Retrieved on 2007-04-02.</ref>

==References==
{{Reflist|2}}


{{Muscle relaxants}}
{{Nicotinic acetylcholine receptor modulators}}

[[Category:Muscle relaxants]]
[[Category:Nicotinic antagonists]]
[[Category:Withdrawn drugs]]
[[Category:Quaternary ammonium compounds]]
[[Category:Piperidines]]
[[Category:Acetate esters]]
[[Category:Propionates]]
[[Category:Steroids]]